These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24570189)

  • 1. [Do antibodies provide advantages for the therapy of Alzheimer's disease? Solanezumab: the jury is still out].
    Peters O
    Dtsch Med Wochenschr; 2014 Mar; 139(10):468. PubMed ID: 24570189
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
    Salloway S; Sperling R; Brashear HR
    N Engl J Med; 2014 Apr; 370(15):1460. PubMed ID: 24724181
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
    de la Torre JC
    N Engl J Med; 2014 Apr; 370(15):1459-60. PubMed ID: 24716689
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
    Laske C
    N Engl J Med; 2014 Apr; 370(15):1459. PubMed ID: 24716688
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
    Doody RS; Farlow M; Aisen PS;
    N Engl J Med; 2014 Apr; 370(15):1460. PubMed ID: 24716687
    [No Abstract]   [Full Text] [Related]  

  • 6. Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.
    Imbimbo BP; Ottonello S; Frisardi V; Solfrizzi V; Greco A; Seripa D; Pilotto A; Panza F
    Expert Rev Clin Immunol; 2012 Feb; 8(2):135-49. PubMed ID: 22288451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunotherapy for Alzheimer's disease].
    Falkentoft AC; Hasselbalch SG
    Ugeskr Laeger; 2016 Jan; 178(3):V07150588. PubMed ID: 26815584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiamyloid therapy for Alzheimer's disease--are we on the right road?
    Karran E; Hardy J
    N Engl J Med; 2014 Jan; 370(4):377-8. PubMed ID: 24450897
    [No Abstract]   [Full Text] [Related]  

  • 9. Solanezumab and the amyloid hypothesis for Alzheimer's disease.
    Le Couteur DG; Hunter S; Brayne C
    BMJ; 2016 Dec; 355():i6771. PubMed ID: 28034844
    [No Abstract]   [Full Text] [Related]  

  • 10. Sixty seconds on . . . solanezumab.
    Hawkes N
    BMJ; 2016 Nov; 355():i6389. PubMed ID: 27899350
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
    Doody RS; Thomas RG; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; Raman R; Sun X; Aisen PS; Siemers E; Liu-Seifert H; Mohs R; ;
    N Engl J Med; 2014 Jan; 370(4):311-21. PubMed ID: 24450890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
    Rygiel K
    Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biogen's aducanumab raises hope that Alzheimer's can be treated at its source.
    Patel KR
    Manag Care; 2015 Jun; 24(6):19. PubMed ID: 26182718
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
    Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R
    Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
    Panza F; Solfrizzi V; Imbimbo BP; Logroscino G
    Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aducanumab Therapy Ameliorates Calcium Overload in a Mouse Model of Alzheimer's Disease.
    Gamage KK; Kumar S
    J Neurosci; 2017 Apr; 37(17):4430-4432. PubMed ID: 28446659
    [No Abstract]   [Full Text] [Related]  

  • 17. Antibody drugs for Alzheimer's show glimmers of promise.
    Reardon S
    Nature; 2015 Jul; 523(7562):509-10. PubMed ID: 26223602
    [No Abstract]   [Full Text] [Related]  

  • 18. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    Rabinovici GD
    N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284
    [No Abstract]   [Full Text] [Related]  

  • 19. Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.
    Bouter Y; Lopez Noguerola JS; Tucholla P; Crespi GA; Parker MW; Wiltfang J; Miles LA; Bayer TA
    Acta Neuropathol; 2015 Nov; 130(5):713-29. PubMed ID: 26467270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab.
    Lachno DR; Evert BA; Vanderstichele H; Robertson M; Demattos RB; Konrad RJ; Talbot JA; Racke MM; Dean RA
    J Alzheimers Dis; 2013; 34(4):897-910. PubMed ID: 23302661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.